Amyotrophic Lateral Sclerosis (ALS) and Psoriasis patients receive Brazilian government permission to be treated

Medical Marijuana, Inc. (MJNA) è la prima azienda quotidiana di cannabis in commercio negli Stati Uniti. La sua controllata HempMeds® Brasil ha annunciato oggi che il prodotto petrolifero cannabidiolo cannabidiolo (CBD) della società è stato prescritto da medici nel paese per il trattamento dei pazienti affetti da sclerosi laterale amyotrofica (ALS) e psoriasi.

 

Questo segna la prima volta che i medici brasiliani prescrivono RSHO ™ per aiutare specificamente i pazienti affetti da effetti debilitanti di una di queste due malattie. Ciò avviene due anni dopo che HempMeds® Brasil è divenuto la prima azienda a offrire prodotti medicinali di cannabis medicinali ai pazienti del paese.

“Il governo brasiliano ha dimostrato ancora una volta che la salute e il benessere del loro popolo sono qualcosa che sono interessati a sostenere continuando a dare loro l’accesso ai prodotti petroliferi di canapa del CBD per pazienti affetti da condizioni senza cure conosciute o opzioni di trattamento limitate, “Ha detto il dottor Stuart Titus, Chief Executive Officer della Medical Marijuana, Inc.” L’ALS è una condizione deliberante che fino ad oggi non ha trattamenti disponibili e la psoriasi è una condizione molto comune che colpisce milioni e siamo entusiasti del futuro per CBD- Per accedere alle sperimentazioni cliniche per queste due condizioni “.

Secondo la relazione globale sulla psoriasi dell’Organizzazione mondiale della sanità , il numero di persone in tutto il mondo con la psoriasi è in aumento, con circa 125 milioni di persone colpite in tutto il mondo, ovvero circa il 2% al 3% della popolazione mondiale. Solo in Brasile, si stima che oltre 2 milioni di persone hanno la malattia e più di 7,5 milioni negli Stati Uniti. Secondo la ricerca sul mercato della trasparenza , il mercato globale per il trattamento della psoriasi è stato di 7,8 miliardi di dollari nel 2015 e si prevede di crescere a 12,1 miliardi di dollari entro il 2024.

La sclerosi laterale amiotrofica (ALS), nota anche come malattia di Lou Gehrig o malattia del motoneurone (MND), è una malattia specifica che causa la morte dei neuroni che controllano i muscoli volontari. È una malattia neurodegenerativa progressiva che colpisce le cellule nervose del cervello e del midollo spinale. La malattia colpisce circa 30.000 negli Stati Uniti e oltre 450.000 in tutto il mondo senza alcuna cura nota disponibile finora.

A proposito di HempMeds ® Brasil
HempMeds® Brasil ha attualmente tre prodotti di cannabis autorizzati per l’importazione nella Brasile come una prescrizione di farmaci per molteplici condizioni tra cui; Epilessia, Parkinson, dolore cronico, psoriasi, cancro, Alzheimer, diabete, sclerosi laterale amyotrofica, sclerosi multipla e emicranie. L’azienda ha ottenuto il primo prodotto di cannabis per l’importazione in Brasile ei suoi prodotti sono attualmente sovvenzionati dal governo brasiliano, sotto il loro sistema sanitario, per tutte e tre le indicazioni mediche sopra elencate. HempMeds® Brasil sta lavorando ad approvazioni aggiuntive per più indicazioni.

A proposito di Medical Marijuana, Inc.
La nostra missione è quella di essere premier innovatori del settore cannabis e canapa, sfruttando il nostro team di professionisti per la fonte, la valutazione e l’acquisto di aziende e prodotti a valore aggiunto, consentendo loro di mantenere la loro integrità e spirito imprenditoriale. Ci sforziamo di creare consapevolezza all’interno del nostro settore, sviluppare le imprese ecocompatibili e economicamente sostenibili, aumentando il valore degli azionisti. Per ulteriori informazioni sul portafoglio e sulle società di investimento di Medical Marijuana, Inc., visitare il sito http://www.medicalmarijuanainc.com .

 

http://420intel.com/articles/2017/07/19/amyotrophic-lateral-sclerosis-als-and-psoriasis-patients-receive-brazilian?utm_source=420+Intel+-+Marijuana+Industry+News&utm_campaign=da9f477993-420+Intel&utm_medium=email&utm_term=0_3210cbef52-da9f477993-270890321

Legal cannabis sales begin in Uruguay under landmark 2013 law

“Uruguay is at the forefront of the world on this”: Marijuana can now be purchased at 16 pharmacies across the country

MONTEVIDEO, Uruguay — Marijuana aficionados lined up at pharmacies across Uruguay on Wednesday to be among the first in the South American nation to legally buy pot as a law regulating its sale took full effect.

Customers sniffed pungent green buds and grinned as they showed off blue-and-white envelopes containing the plant, which is now available as part a 2013 measure that made Uruguay the first nation to legalize a pot market covering the entire chain from plants to purchase.

Related: Inside story on Uruguay, where the government is your weed dealer

Santiago Pinatares, a 35-year-old construction worker, braved freezing temperatures in the capital, Montevideo, as he waited outside one of the 16 pharmacies authorized to sell marijuana. He said he has been smoking pot since age 14 but had no choice but to buy on the black market until now.

“To be able to buy it legally is a huge breakthrough,” he told The Associated Press. “Uruguay is at the forefront of the world on this.”

Story continues below photo gallery 

People line up outside a pharmacy selling legal marijuana in downtown Montevideo, Uruguay, Wednesday, July 19, 2017. Marijuana is going on sale at 16 pharmacies in Uruguay, the final step in applying a 2013 law that made the South American nation the first to legalize a pot market covering the entire chain from plants to purchase. (Matilde Campodonico, The Associated Press)

Some customers declined to comment saying they didn’t want their families or employers to know they were buying marijuana.

Authorities say nearly 5,000 people have registered as consumersallowing them to buy up to 40 grams per month using fingerprint recognition. About two-thirds of them live in Montevideo.

The price is set at the equivalent of $1.30 per gram, with 90 cents of that going to the two businesses chosen to cultivate marijuana.

The rest is split between the pharmacies and the government, which will use its share to fund prevention programs. The marijuana comes in packages emblazoned with a seal of authenticity and warnings about the drug’s effects.

Uruguay became the first country to regulate a national marijuana marketplace in an effort to fight rising homicide and crime rates associated with drug trafficking. The law also lets licensed individuals grow marijuana plants and form clubs.

The country’s marijuana plan was widely applauded globally and seen as going beyond marijuana legislation in the U.S. states of Colorado and Washington, but polls showed that most Uruguayans opposed it.

Most of the country’s estimated 1,200 pharmacies also decided not to register to sell, stoking a debate over how the drug should be distributed. Experts attributed delays in the implementation of the pioneering plan to the fact that no other country had attempted such an ambitious endeavor.

“There was a lot of hard work to finally come to this day,” Drug czar Diego Olivera said. “It is a challenging and complex project, and today we have taken a step forward.”

 

 

http://www.thecannabist.co/2017/07/18/uruguay-marijuana-pharmacies-sales/83968/

ISRAELI DOCTOR LAUNCHING CLINICAL TRIAL ON MEDICAL MARIJUANA AND AUTISM

ANECDOTAL EVIDENCE OF MARIJUANA HELPING SYMPTOMS OF AUTISM GETTING TESTED IN CLINICAL TRAIL


Israeli Doctor Launching Clinical Trial On Medical Marijuana And Autism – Dr. Adi Eran, is heading up the autism and medical marijuana clinical trial. The study is in the process of getting permits from the Israeli Health Ministry for the study. The study will involve 120 autistic individuals, male and female, aged 4 to 30, low to medium on the spectrum of functioning.
The study will administer CBD (cannabidiol) oil with trace amounts of THC.
Eran, head of the pediatrics neurology department at Shaare Zedek Medical Center in Jerusalem, has obtained the authorization in principle from the Israel Health Ministry for his tests. He is finding subjects from local hospitals, and psychiatric facilities and centers dealing with childhood development.

THE STUDY OUTLINE

The participants will be divided into two groups: the test group that actually ingests the oil, and the control subjects who will be given placebos. After a test period during which the effects on the patients will be recorded, treatment will be halted for a month, then the groups will be reversed – the test group will become the control group and vice versa. Again, as is typical in such research, at no point will subjects or their families know whether the patient is receiving CBD or a placebo.

The study will focus specifically on a certain segment of behavioral symptoms typical of certain autistic individuals, including physical aggression toward themselves and others, attacks that can be accompanied by acute anxiety.

RISKS AND UNCERTAINTY

and how it could be prescribed to treat autism – a process that includes defining the “severe behavioral problems” that would require use of the substance.
As of right now cannabis oil is not recognized as a form of treatment for autism, Dr. Eran explains, several dozen Israelis who suffer from the disorder have received approved prescriptions for the drug because of the severity of their symptoms and behavior – mainly because nothing else helped them. The families know cannabis isn’t a recognized treatment but had nothing to lose, the specialist says, although he stresses that its merit has yet to be tested under rigorous conditions. Now it will be.

ANECDOTAL EVIDENCE

Naama Saban, a pediatric nurse, says treatment with CBD oil three times a day made the patients significantly calmer and less violent.

“It isn’t that they’re stoned because the oil has no psycho-active component,” Saban says. “Their parents say the quality of life has completely changed. That for the first time, their little kids can have friends over and the big brother doesn’t go wild.”

https://medicalmarijuana411.com/israeli-doctor-launching-trial-on-medical-marijuana-autism/?utm_source=newsletter071317&utm_medium=email&utm_campaign=dailydose&utm_content=readmore

Inserimento lavorativo per disabili, concluso il primo stage

Now in Sicily

Giovanni, Dario e Giuseppe: sono loro i protagonisti del primo stage di inserimento lavorativo di giovani con disabilità promosso e portato avanti dallo studio Parentage di Catania.
Lo stage, che si è concluso lo scorso 13 luglio, si è articolato in 10 incontri distribuiti in 1 mese, 2 volte alla settimana. I 3 ragazzi coinvolti presentano patologie del neurosviluppo, in particolar modo deficit cognitivo e disturbo dello spettro autistico.

“Grazie a questo progetto – dicono le dottoresse dello studio Parentage – abbiamo raggiunto importanti obiettivi tra cui l’inclusione attiva e partecipe dei ragazzi speciali nel contesto lavorativo; la crescita personale indirizzata all’autonomia e all’indipendenza; l’acquisizione di strumenti base per diventare un bravo cameriere”.

I ragazzi, che hanno lavorato presso la trattoria Taverna dei Conti, hanno svolto diverse mansioni come la sistemazione dei tavoli, bicchieri, piatti e posate negli appositi contenitori, l’approccio alla raccolta differenziata, il servizio al tavolo e la…

View original post 140 altre parole

Cannabis: La Camera dà via libera alle firme sulla legge popolare per la legalizzazione

La Presidente della Camera Laura Boldrini ha comunicato oggi all’Associazione Luca Coscioni e Radicali Italiani che il controllo dei certificati elettorali consegnati l’11 novembre scorso a sostegno di una proposta di legge d’iniziativa popolare per la regolamentazione legale della produzione, consumo e commercio della cannabis e suoi derivati si è conclusa con successo e che il testo verrà adesso assegnato alle commissioni competenti.

La Presidenta Boldrini, che sappiamo esser molto attenta al contributo della società civile ai lavori istituzionali,” ha dichiarato Filomena Gallo, Segretario dell’Associazione Luca Coscioni “ha voluto aggiornare al 2017 la prassi del controllo dei certificati elettorali che, in parte, abbiamo consegnato in formato digitale, considerandoli validi. Anche a nome degli altri promotori e degli oltre 60mila cittadini che hanno sottoscritto la proposta di legge la ringraziamo per questo. Ci appelliamo alle Commissioni giustizia e affari sociali affinché rigettino la proposta dello stralcio della parte terapeutica dell’Onorevole Miotto e proseguano con l’iter sulla legalizzazione totale bloccato da quasi un anno.

Riccardo Magi, Segretario di Radicali Italiani ha dichiarato: “E’ un grande successo di mobilitazione che siamo riusciti a ottenere nonostante gli enormi ostacoli burocratici e procedurali alla partecipazione popolare. Con la nostra proposta di legge popolare il Parlamento ha un’occasione in più, che gli viene offerta dai cittadini, di conquistare una riforma di buon senso come la legalizzazione della cannabis che oggi mette d’accordo decine di magistrati e la Direzione Nazionale Antimafia perché sottrarrebbe soldi alle mafie e li porterebbe all’erario, riscattando milioni di consumatori dal mercato criminale e liberando risorse per la giustizia. Continua quindi la lotta radicale per le libertà dei cittadini e per semplificare le procedure di raccolta firme su referendum e leggi popolari.

I dati che abbiamo presentato con il libro bianco sulla legge Fini-Giovanardi pubblicato colle associazioni del Cartello di Genova” ha concluso Marco Perduca, coordinatore di Legalizziamo.it “confermano che le droghe in Italia sono fuori controllo e che non aver datoseguito alla sentenza della Consulta del 2014 che ha smontato la legge sulla droga sta facendo di nuovo riempire le carceri. Parlamento e Governo collaborino per una regolamentazione legale a partire da una depenalizzazione complessiva di coltivazione, uso e possesso personale” .

Da maggio, tutti i sabati, Mario Staderini, già Segretario di Radicali Italiani con a turno a Marco Gentili, co-Presidente dell’Associazione Luca Coscioni, Leonardo Monaco, Segretario dell’Associazione Radicale Certi Dritti, Filomena Gallo e Marco Perducahanno manifestato con un “duran adam” – la nonviolenza resa famosa dai fatti di Piazza Taksim a Istanbul – davanti al Quirinale attirare l’attenzione del Presidente della Repubblica su quanto sta accadendo in Italia relativamente agli strumenti di iniziativa popolare, in particolare ai referendum e le leggi d’iniziativa popolare.


La legge popolare Legalizziamo! è promossa dall’Associazione Luca Coscioni e Radicali Italiani con il sostegno di A Buon Diritto, Coalizione Italiana per le Libertà Civili e Democratiche, Forum Droghe, Antigone, La PianTiamo, Società della Ragione,  Federazione dei Giovani Socialisti, vari gruppi di Giovani Democratici e circoli ARCI in ordine sparso, il Coordinamento Nazionale dei grow-shop, Canapa Info Point, ASCIA, Possibile a livello nazionale e decine di consiglieri comunali di Sinistra Italiana e anche del Movimento 5 Stelle, del Partito Democratico nonché di liste civiche e indipendenti.

Ecco cosa prevede la proposta di legge Legalizziamo! per la regolamentazione della produzione, del consumo e del commercio della cannabis e suoi derivati.

1. Auto-coltivazione libera fino a cinque piante, con comunicazione da sei a 10.

2. Possibilità di associazione in cannabis social club non a fini di lucro (fino a un massimo di 100 componenti che possono coltivare
cinque piante femmine a testa).

3. Coltivazione e fini commerciali previa comunicazione dell’inizio della coltivazione, nome e varietà di cannabis utilizzate e quantità
di seme per ettaro.

4. Sulle confezioni dei prodotti sarà specificato il livello di THC, la provenienza geografica e l’avvertimento che “un consumo non
consapevole può danneggiare la salute”.

5. I rivenditori non potranno essere nelle immediate vicinanze delle scuole né sarà possibile pubblicizzare i prodotti.

6. Promozione ulteriore dell’accesso ai cannabinoidi medici ampliandolo chiaramente ai malati affetti da sintomatologie che
rispondano favorevolmente ai preparati.

7. Controllo della produzione è affidato alla direzione generale sulle frodi agro-alimentari del Ministero delle politiche agricole e dal
Comando carabinieri per la tutela della salute presso il Ministro della salute.

8. Relazione annuale al Parlamento.

9. Tassazione mutuata dal “Testo unico delle disposizioni legislative concernenti le imposte sulla produzione e sui consumi e relative
sanzioni penali e amministrative” del 1995.

10. Sanzioni amministrative fino a un massimo di 5000 euro per chi viola la nuova normativa.

11. Nuovi introiti destinati a: 10% per campagne informative, 15% per attività di previdenza sociale, 15% per  attività di assistenza
sociale, 20% per la riduzione delle imposte sul lavoro e impresa e per il finanziamento di incentivi all’occupazione, 30% per investimenti
produttivi, il rimanente 10% per la  riduzione del debito pubblico.

12. Vengono infine abolite tutte le sanzioni penali anche per l’uso personale di tutte le altre sostanze proibite e si introduce una norma
volta alla scarcerazione di coloro che hanno subito una condanna relativa a condotte legalizzate con la proposta di legge.

 

 

https://www.associazionelucacoscioni.it/notizie/comunicati/cannabis-la-camera-via-libera-alle-firme-sulla-legge-popolare-la-legalizzazione/

Zinbryta: restrizioni in Europa, dopo un caso di decesso e numerosi casi di gravi danni epatici

flipout4ms

Cari lettori, ci arrivano dall’America brutte notizie dal fronte della distribuzione dei farmaci per la SM. La European Medicines Agency (Agenzia europea dei medicinali) ha infatti limitato l’uso del farmaco Zinbryta (daclizumab), ampiamente impiegato per la Sclerosi Multipla recidivante remittente (SMRR), dopo che sono stati riportati alcuni casi di pazienti che hanno subito gravi danni epatici e un caso di decesso in seguito a complicanze ematologiche ed epatiche. 

L’ordine temporaneo limita Zinbryta ai pazienti dell’Unione europea con una malattia altamente attiva che non hanno reagito ad altre terapie DMT e ai pazienti con una malattia in rapida evoluzione che non possono essere trattati con altri farmaci.

Nel frattempo, l’agenzia sta esaminando attentamente il profilo di sicurezza del farmaco di Biogen, secondo quanto affermato in un recente comunicato stampa.

needle-2

L’amministrazione federale degli Stati Uniti , che, come gli enti regolatori europei, è consapevole del fatto che il farmaco Zinbryta…

View original post 597 altre parole

Israeli Study Shows Medical Cannabis Can Treat Autism In Children

An Israeli study currently underway is finding that medical cannabis can be used to treat the symptoms of autism in children and adults.

According to the Center for Disease Control (CDC), in 2012, one in every 68 children(1.5 percent) in the United States were diagnosed with autism spectrum disorder (ASD). They also found that the condition affects every race, gender, and socioeconomic group.

The disorder is often diagnosed when the child is around the age of two, when they demonstrate impaired social skills and communication abilities along with compulsive behaviors. Meanwhile, the costs of medical care, special education, and lost parental productivity weighs on the families; the annual total costs in the United States for children with ASD is estimated to be between about $11.5 billion and $60.9 billion.

Dr. Adi Aran, an Israel neurologist, may be able to offer the families some reprieve.

Dr. Aran is the Director of the Neuro-pediatric unit in Shaare Zedek Medical Center and his latest research involves treating the symptoms of autism using medical marijuana. “So far,” Aran tells NoCamels, “our impression is that it’s working.”

“In autism, it is the first of the field.”

Currently, only two atypical antipsychotic drugs are approved by the Food and Drug Administration (FDA) to treat symptoms of autism in the US. However, like many medications, they do not work for all patients and they can have serious side effects like weight gain and altered hormone production according to a 2008 study in the Journal of Clinical Investigation.

ASD can also be treated with intensive behavioral therapies which require high levels of care ideally performed by both professionals and the parents. As Aran explains, “Before we started the study, many parents came to us and they asked for help for their children. Medications and all sorts of behavioral therapy methods didn’t help and they had heard about some reports that medical cannabis might help. In the beginning, we didn’t give them anything because it wasn’t proven,” explains Aran.

However, the parents persisted and Aran acquiesced. “Eventually we decided that it was worth checking because the families were really helpless. The quality of life was very poor.”

Dr. Aran set up the first ever clinical trial examining whether cannabis oil can treat children with autism. While he is “aware of some studies that are on their way in Israel and the United States but there are no other studies started yet.”

The clinical study began in January 2017 in Jerusalem at the Shaare Zedek Medical Center. There are 120 participants, including children and young adults, diagnosed with various degrees of ASD ranging from mild to severe. Dr. Aran hopes to have final results by December 2017.

How does it work?

According to Dr. Aran, “there are theories” for why medical cannabis can alleviate symptoms of autism, “but we don’t know exactly how. There are theories and models but we don’t know. It can’t be explained.”

This is worrisome given that cannabis is being given to children with little knowledge of why or how it may help. Of course, “We are worried with children because of the long-term impact. But it is considered mostly safe and we have already tested it with epilepsy.” Other studies, like the one published in Seizure: European Journal of Epilepsy 2016, conducted in Israel, successfully demonstrated that cannabis reduced the number of seizures of children with epilepsy. Nonetheless, Aran admits that “There are always worries that something will happen that we don’t know about.”

It is key to note that the participants are receiving cannabidiol (CBD), a non-psychoactive compound, as opposed to the more commonly known tetrahyrdrocannabinol (THC), which creates the “high” feeling. Therefore, the benefits they seem gain from the treatment “help the children cooperate more,” reduce behavioral problems, and “improve their functioning.”

Israel: the forefront of cannabis research

Israel is one of the first modern nations to investigate the medical benefits of marijuana. The local founding father of cannabis research, Prof. Raphael Mechoulam of the Hebrew University, has been studying the plant since the 1960s. In fact, he discovered THC in 1964. Over the subsequent decades, other researchers around the world have joined him to explore cannabis’ potential medical applications.

In particular, Israel’s government sponsors a medical cannabis program and limits restrictions on such research unlike in the US. Some recent Israeli studies show that marijuana can heal bone fractures, relieve the pain associated with Parkinson’s disease, prevent brain damage, and even halt the spread of cancer.

Asked why Israel is such a medical cannabis research powerhouse, Aran concurred saying, “I’m sure that the government has a lot to do with it…They expedite things, not taking too long” with few legal restrictions and low cost.

While the study offers much hope for the children and families affected by ASD, Aran warns that “It won’t cure the symptoms, that’s for sure. It will never cure autism. But it certainly can help the quality of life of the families.”

That alone is quite a high goal to reach.

http://420intel.com/articles/2017/07/12/israeli-study-shows-medical-cannabis-can-treat-autism-children?utm_source=420+Intel+-+Marijuana+Industry+News&utm_campaign=f92c3884f5-420+Intel&utm_medium=email&utm_term=0_3210cbef52-f92c3884f5-270890321

Trump Will Cripple States If He Reverses Marijuana Legalization

If President Donald Trump reverses state laws legalizing marijuana, he could cripple if not bankrupt those states.

Last month I gave the keynote address at the Cannabis World Congress Business Expo in New York City. CWCBExpo is the trade show for the cannabis industry. I had the pleasure of meeting thousands of like-minded cannabis activists, and the experience was truly refreshing and inspiring on many levels.

I learned firsthand that those in the legal cannabis industry — whether they’re growing hemp, medical marijuana or recreational marijuana in California or Oregon or wherever — have formed a united front. Everyone at the convention was looking to work together to come up with solutions on how to get the federal government to move forward and embrace this industry, which has grown exponentially.

When it comes to economics, let me put the state of marijuana to you in this way: If Trump reverses state law, he’ll be crippling if not bankrupting the states that have legalized marijuana. Not only will this action go against the will of the people who voted for legalized marijuana, this action will cause yet another economic collapse. And no, that isn’t an exaggeration.

Over half of the states have now legalized marijuana in some way and multiple states are receiving millions, soon to be billions, in tax revenue from this industry. When those states no longer have this tax revenue coming in (tax revenue that is projected to increase steadily each year), where will that money come from?

Think about it this way: The auto industry was bailed out with roughly $80 billion from taxpayer money, but it is still here, and the industry was able to repay taxpayers overtime. We’re talking about making a profitable, multibillion-dollar industry go away overnight. Meaning America’s president will voluntarily make hundreds of thousands of Americans unemployed overnight. How many will default on their mortgages? How many will declare personal bankruptcy?

A report by New Frontier Data states the marijuana industry is projected to create a quarter of a million jobs by 2020 — that’s more jobs than the manufacturing industry, utilities, or government jobs, according to the Bureau of Labor Statistics. Prior to the 2016 election, the marijuana industry, which existed in 25 states at the time, was worth a combined $7.2 billion. Now, this industry is expected to grow at a compounded annual rate of 17 percent, with medical marijuana sales growing from $4.7 billion in 2016 to $13.3 billion in 2020. Adult recreational sales (recreational use is only available in eight states) are expected to go from $2.6 billion in 2016 to $11.2 billion by 2020.

“If Trump reverses state law, he’ll be crippling if not bankrupting the states that have legalized marijuana. Not only will this action go against the will of the people who voted for legalized marijuana, this action will cause yet another economic collapse.”

Colorado alone has a $1.3 billion marijuana industry and much of the tax money is going toward scholarships so students can go to community colleges for free. This isn’t “found money” either. Before marijuana was legal, this money was going to the black market, to the drug cartels. Now it’s being used to fund college scholarships. Let that sink in for a minute. In the Denver metro area, marijuana tax dollars are being used for infrastructure. Imagine that. We don’t need to rely on false presidential promises to fix our local roads and bridges. The town of Edgewater is spending $1.4 million in marijuana tax revenue to repave streets and replace their city hall with a new building that includes a police station and library.

My point is this: When an entire industry is taken away from states like Colorado, California, Oregon, Washington and so on, how does President Trump expect our nation to recover? It is estimated that California will take in $1 billion from marijuana sales tax once dispensaries start selling recreational marijuana in 2018. The cannabis industry is an industry that is bringing back American farms — which means rural areas which have been struggling finally have the chance to thrive — not just through marijuana but through hemp farming. And don’t forget: this is an industry that relies solely on an American work force. The cannabis industry is all-American and comprised of American entrepreneurs, employees, and customers. There’s no way to outsource labor to other countries. And unlike all those infuriating stereotypes, this is an industry of educated and informed individuals.

To be successful, American cannabis business owners have to stay up-to-date on new laws and regulations — that means many are spending their time fighting against unjust laws and regulations, all while running a company with their own capital. This entire industry is unable to get a bank loan or set up a bank account due to federal law. When you can’t rely on a bank to even store your money, you’re wearing more hats than any other small business owner or entrepreneur.

If federal law doesn’t change by the time Canada legalizes marijuana nationwide in 2018, just watch our neighbors to the north find a way to get their banking system on board for American cannabis businesses. And get ready for American cannabis businesses to go to Canada, or at least set up a headquarters there. Many are already going to Puerto Rico, where the IRS Tax Code 280E doesn’t apply. Don’t know what that is? Well, you know how businesses can deduct expenses on their taxes? If you’re working with marijuana, you can’t deduct anything because of 280E. Of course, there’s also Mexico. Our neighbors to the south just legalized medical marijuana, so who knows how many American researchers will be crossing the border to study this plant.

The president doesn’t have the power to overturn votes

If someone ran a successful, legal business that could be taken away at any time because President Trump felt like it, then yes, that person would probably consider moving to another country to survive. But that’s not what I discussed at the CWCBExpo. I didn’t plead with these businesses to make as much money as possible and then use that money to get the hell out before it’s too late. That’s not the united front the American cannabis industry is after. These are hopeful, optimistic business owners who have watched cannabis laws slowly change in their favor, and they’re doing all that they can to work with lawmakers and educate citizens to continue that trend. This American industry is looking not just to make history but to make America a better place for generations to come. Their tax money is making a significant difference in their local communities — how many of us see our taxes directly contribute to anything worthwhile (and by worthwhile I mean schools, roads, libraries — not foreign wars).

The cannabis industry is about innovation as much as it is about fighting against oppression. That’s the American way. And it’s all of our jobs as American citizens to remind the federal government what that means: When we the people vote to legalize something, we legalize it. The president doesn’t have the power to overturn our votes. Our faltering economy needs the American cannabis industry to continue to grow and succeed. It’s really that simple. Why we’re even debating this is beyond me.

http://420intel.com/articles/2017/07/12/trump-will-cripple-states-if-he-reverses-marijuana-legalization?utm_source=420+Intel+-+Marijuana+Industry+News&utm_campaign=f92c3884f5-420+Intel&utm_medium=email&utm_term=0_3210cbef52-f92c3884f5-270890321

CBD research is going to the dogs in quest to help pets

Cannabist Special Report: CBD, TBD || Veterinarians at Colorado State University and beyond are spearheading clinical studies on the effectiveness of cannabidiol in treating canine ailments

 

Cannabidiol is a non-psychoactive cannabis compound touted for its medicinal promise — but marijuana- and hemp-derived extracts rich in CBD and low in intoxicating THC are facing a future yet to be determined.

The Cannabist’s special report “CBD, TBD” explores a regulatory and legal landscape pockmarked by federal-state conflicts, and examines national drug policy, pioneering research efforts and disparate avenues toward the compound’s full legalization. This is the fourth installment in an ongoing series.

Part I – Forbidden medicine: Caught between a doctor’s CBD advice and federal laws

Part II – How advocates are inspiring congressional action on CBD legalization

Part III – With DEA digging in its heels on “marijuana extracts,” legality of CBD oil on trial in federal courts


FORT COLLINS — Riley lumbered into the laboratory and greeted scientists with hefty, loving nudges and sloshes of slobber.

The 135-pound Newfoundland is a favorite at the Colorado State University Veterinary Teaching Hospital, where she’s among a few dozen pooches participating in one of the first scientific clinical trials assessing the efficacy of cannabidiol in treating certain canine ailments.

The non-psychoactive cannabis compound isn’t just hailed for its potential medicinal benefits in humans — the anecdotal evidence emerging from legal marijuana states has some pet owners wondering if CBD could be a life-improving medicine for man’s best friend. In Colorado, CBD-rich whole plant hemp extracts already are available for purchase online or at the neighborhood pet shop down the street.

However, scientists and veterinarians caution that clinical research is lacking, dogged by complications — notably marijuana’s Schedule I status and CBD’s shaky legal standing as it relates to another more familiar cannabis compound: psychoactive delta-9 tetrahydrocannabinol (THC), which can be toxic to animals.

CSU veterinary neurologist Dr. Stephanie McGrath began fielding queries about CBD’s therapeutic powers for pets after Colorado legalized recreational marijuana and cultivation of industrial hemp in 2012. Owners and vets alike called to inquire about the safety and efficacy of administering CBD to pups for everything from sore hips, to seizures, to anxiety caused by fireworks and thunderstorms.

What McGrath heard was extremely disappointing, she said. Some pet owners were dosing animals with their own edibles or other medical marijuana products procured to treat human ailments.

“That, as you can imagine, is not safe at all,” she said.

In addition to her concerns with the DIY nature of the dosing, McGrath said she was skeptical of what was being packaged and sold in pet stores. No qualified, peer-reviewed scientific studies had been conducted on CBD products for pets, she realized.

“Looking at it from a scientific standpoint and as a doctor, I felt really uncomfortable with the products being offered,” she said.

Whether it’s THC-laden marijuana or industrial hemp with traces of that illicit compound, cannabis is a Schedule I substance. The uncertain legal landscape surrounding CBD oil — even the hemp-derived variety — has stymied studies for humans and animals alike.

Its murky legal status doesn’t just impede access to the whole hemp plant extract, said Michael San Filippo, spokesman for the American Veterinary Medical Association. It also makes it difficult for scientists to receive the blessing — and funding — for CBD research from major academic institutions wary of crossing federal boundaries, he said.

As such, the science isn’t there yet on aspects such as CBD’s effectiveness and dosing, San Filippo said.

“There are a lot of unanswered questions,” he said.

 

http://www.thecannabist.co/2017/07/12/cbd-pet-products-dogs-cannabidiol-research/83474/